Pfizer agrees to buy Metsera for up to $7.3 billion
Pfizer agreed to buy obesity drug developer Metsera for $47.50 a share in cash plus up to $22.50 more tied to milestones, adding monthly-dose GLP-1 and amylin shots that are still years from any approval [1].
Pfizer said on September 22, 2025, that it has signed a definitive agreement to acquire Metsera, a clinical-stage company working on obesity and cardiometabolic drugs. Pfizer will pay $47.50 per Metsera share in cash at closing, an initial enterprise value of about $4.9 billion, plus a non-transferable contingent value right (CVR) worth up to an additional $22.50 per share if certain milestones are hit [1]. Both companies' boards approved the deal unanimously [1].
The CVR is split into three payments tied to specific events: $5 per share when a Phase 3 trial starts for Metsera's MET-097i plus MET-233i combination, $7 per share if the FDA approves monthly MET-097i on its own, and $10.50 per share if the FDA approves the monthly MET-097i plus MET-233i combination [1]. None of those payments happen unless the milestones are actually achieved [1].
What Pfizer is buying
Metsera has four programs in clinical testing. MET-097i is an injectable GLP-1 receptor agonist being developed in both weekly and monthly versions, and both are in Phase 2 [1]. MET-233i is a monthly amylin analog candidate, currently in Phase 1, being studied alone and in combination with MET-097i [1]. Two oral GLP-1 candidates are expected to enter clinical trials "imminently," and the company also has preclinical nutrient-stimulated hormone therapeutics [1].
Metsera presented initial Phase 1 results for MET-233i on September 17 as a late-breaker at the 61st Annual Meeting of the European Association for the Study of Diabetes, which Pfizer described as showing a "potential best-in-class profile" [1]. The press release does not include the actual weight-loss numbers, side-effect rates, or participant counts from that presentation, so those details are not available in the source [1].
Pfizer CEO Albert Bourla framed the deal as an entry into a therapeutic area the company has been absent from: "Obesity is a large and growing space with over 200 health conditions associated with it," he said, adding that Pfizer wants to apply its "manufacturing and commercial infrastructure" to a portfolio of "potential best-in-class injectables, with clinical data differentiated by efficacy, tolerability and durability supporting monthly dosing" [1]. Metsera co-founder and CEO Whit Bernard said the company, founded in 2022 and based in New York City, has built "multiple injectable and oral candidate medicines and a category-leading peptide engineering platform" [1].
The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions including required regulatory approvals and a vote by Metsera shareholders [1]. Pfizer said it will update its financial outlook alongside its next quarterly earnings [1].
Why it matters for patients
Nothing about this deal changes what is available at the pharmacy today. Metsera's most advanced candidate is in Phase 2, and its amylin candidate is in Phase 1 [1]. Drugs at that stage typically face years of additional testing before any FDA decision, and many never reach approval. The CVR structure itself acknowledges that: Pfizer only owes the larger payments if the FDA actually approves the monthly monotherapy and the monthly combination [1].
The strategic signal is about where obesity treatment may be headed. Metsera's pitch is "fewer injections while achieving improved efficacy and tolerability" — specifically monthly dosing rather than the weekly injections used with semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) [1]. The portfolio also includes an amylin analog, a non-incretin approach that works differently from GLP-1 drugs and is being tested in combination with one [1]. If those approaches pan out, patients could eventually have more choices in how often they inject and which hormone pathways a drug targets.
A large company entering the field also means more money behind late-stage trials. Whether that translates into lower prices or broader insurance coverage is not addressed anywhere in the announcement and is not yet known [1].
What happens next
Metsera shareholders must vote on the deal, and regulators must sign off, with closing targeted for the fourth quarter of 2025 [1]. Pfizer said it will host an investor webcast at 8 a.m. EDT on September 22, with a transcript and replay posted within 24 hours and available for at least 90 days [1]. Pfizer also cautioned that competing offers are possible and that the acquisition may not close at all [1].
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.